Terms: = Breast cancer AND STAT5B, STAT5, 6777, ENSG00000173757, P51692 AND Clinical Outcome
8 results:
1. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary breast cancer Predicts Poor clinical outcome and Correlates with Suppressed stat5 Signaling.
Tran TH; Utama FE; Sato T; Peck AR; Langenheim JF; Udhane SS; Sun Y; Liu C; Girondo MA; Kovatich AJ; Hooke JA; Shriver CD; Hu H; Palazzo JP; Bibbo M; Auer PW; Flister MJ; Hyslop T; Mitchell EP; Chervoneva I; Rui H
Clin Cancer Res; 2018 Dec; 24(24):6355-6366. PubMed ID: 30097435
[TBL] [Abstract] [Full Text] [Related]
2. STAT3 and stat5b polymorphism contributes to breast cancer risk and clinical outcomes.
Zhao L; Zhang Q; Luan X; Huang X; Zhao S; Zhao H
Int J Clin Exp Pathol; 2015; 8(2):2033-8. PubMed ID: 25973100
[TBL] [Abstract] [Full Text] [Related]
3. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract] [Full Text] [Related]
4. Low levels of stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes.
Peck AR; Witkiewicz AK; Liu C; Klimowicz AC; Stringer GA; Pequignot E; Freydin B; Yang N; Ertel A; Tran TH; Girondo MA; Rosenberg AL; Hooke JA; Kovatich AJ; Shriver CD; Rimm DL; Magliocco AM; Hyslop T; Rui H
Breast Cancer Res; 2012 Oct; 14(5):R130. PubMed ID: 23036105
[TBL] [Abstract] [Full Text] [Related]
5. Loss of nuclear localized and tyrosine phosphorylated stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.
Peck AR; Witkiewicz AK; Liu C; Stringer GA; Klimowicz AC; Pequignot E; Freydin B; Tran TH; Yang N; Rosenberg AL; Hooke JA; Kovatich AJ; Nevalainen MT; Shriver CD; Hyslop T; Sauter G; Rimm DL; Magliocco AM; Rui H
J Clin Oncol; 2011 Jun; 29(18):2448-58. PubMed ID: 21576635
[TBL] [Abstract] [Full Text] [Related]
6. Signal transducer and activator of transcription 5A/B in prostate and breast cancers.
Tan SH; Nevalainen MT
Endocr Relat Cancer; 2008 Jun; 15(2):367-90. PubMed ID: 18508994
[TBL] [Abstract] [Full Text] [Related]
7. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling.
Jarrar MH; Baranova A
J Cell Mol Med; 2007; 11(1):71-87. PubMed ID: 17367502
[TBL] [Abstract] [Full Text] [Related]
8. Signal transducer and activator of transcription-5 activation and breast cancer prognosis.
Nevalainen MT; Xie J; Torhorst J; Bubendorf L; Haas P; Kononen J; Sauter G; Rui H
J Clin Oncol; 2004 Jun; 22(11):2053-60. PubMed ID: 15169792
[TBL] [Abstract] [Full Text] [Related]
